In the REMAP-CAP international adaptive platform trial, 1557 critically ill adult patients with COVID-19 were randomized to receive either open-label aspirin, a P2Y12 inhibitor, or no antiplatelet therapy. The gene discussed is P2RY12; the disease is COVID-19.